Post-earnings recap
Reported
Tue, May 6, 2025
EPS actual
$-1.57
EPS est.
$-1.54
EPS surprise
-1.82%
1-day move
-9.80%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Ultragenyx's earnings report reflects ongoing challenges, particularly with their EPS performance, which missed expectations. The stock reacted negatively, dropping 9.8%, likely due to investor concerns about the lack of revenue information and future guidance. This uncertainty may affect investor confidence as the company continues to navigate its clinical programs.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.57 | N/A | -1.82% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding upcoming projects and the current market environment. They emphasized their commitment to advancing their pipeline despite the challenges.
Management did not provide specific guidance for future quarters.
The company is focused on ongoing clinical trials and product development.